Lobbying client · Florida
Vertex Pharmaceuticals Incorporated
Healthcare · Boston
50 Northern Ave, Boston, MA 02210-1862
(813) 205-3348
Lifetime totals
Comp midpoint sum
$195K
Sum of principal_compensation.midpoint across filings
Firms represented
4
Distinct lobbying firms hired
Bills lobbied
8
Quarterly filings
29
Firms hired · 4
Becker & Poliakoff PA4 quarters on retainer · 2025–2026$70K
4 quarterly filings on retainer, from 2025 to 2026.Compensation (bracket midpoint): $70KMagnolia Advocacy LLC9 quarters on retainer · 2025–2026$45K
9 quarterly filings on retainer, from 2025 to 2026.Compensation (bracket midpoint): $45KHarrell Governmental Consulting LLC8 quarters on retainer · 2025–2026$40K
8 quarterly filings on retainer, from 2025 to 2026.Compensation (bracket midpoint): $40KWhitis Consulting LLC8 quarters on retainer · 2025–2026$40K
8 quarterly filings on retainer, from 2025 to 2026.Compensation (bracket midpoint): $40K
Lobbyists on retainer · 53
Individuals who personally lobby for this client, aggregated from the hired firms’ quarterly rosters.
- 20 filings
- 9 filings
- 7 filings
- 6 filings
- 6 filings
- 5 filings
- 4 filings
- 4 filings
- 4 filings
- 4 filings
- 4 filings
- 4 filings
- 4 filings
- 4 filings
- 3 filings
- 2 filings
- 2 filings
- 2 filings
- 2 filings
- 2 filings
- 2 filings
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
- 1 filing
Bills lobbied · 8
- SB 1166: Insurer Disclosures on Prescription Drug CoverageDead
- HB 1209: Pharmacy AuditsDead
- HB 1281: Prohibitions Against Discriminatory Practices relating to 340B Entities and 340B DrugsDead
- HB 353: Sickle Cell Disease Treatment of Pain Continuing EducationDead
- HB 573: Discounted Drug Pricing StudyDead
- SB 844: Sickle Cell Disease Care Management and Treatment Continuing EducationLaw
- HB 697: Drug Prices and CoverageLaw
- HB 1381: Experimental Treatments for Terminal Conditions and Life-threatening Rare DiseasesDead
Year-over-year activity
| Year | Quarters | Comp midpoint |
|---|---|---|
| 2026 | 8 | $65K |
| 2025 | 21 | $130K |